Thermo Fisher, Celltrion compete for Baxter’s biopharma unit, Reuters says

The biopharma solutions business of medical device maker Baxter International (BAX), is being courted by U.S. scientific instruments maker Thermo Fisher Scientific (TMO) and South Korea’s Celltrion, writes Reuter’s Anirban Sen and David Carnevali. "The divestment, which the sources said could fetch more than $4B, would help Baxter pay down debt following its $10.5B acquisition of medical device maker Hill-Rom Holdings in 2021 Other suitors for the Baxter unit include KKR & Co (KKR) and Carlyle Group (CG), added the story. Reference Link